Patient Power
Jay Yang, M.D., hematologist, medical oncologist and leader of the Hematology Oncology Multidisciplinary Team, explains the types of treatments available to myelofibrosis (MF) patients depending on their risk. Genetic mutations, chronic inflammation, certain blood disorders or having been exposed to certain industrial chemicals can influence a person’s risk of developing MF.
Read the article here.